SPRO
Spero Therapeutics, Inc.
There isn't enough reported data to score SPRO yet.
SPRO Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Stable | |
| Weak | |
| Strong |
SPRO's balance sheet is currently strong, and its profitability is stable, but its revenue and cash flow are under pressure.
SPRO PE Valuation
SPRO has no meaningful PE right now: it lost money over the past year.
SPRO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| -- | |
| -- | |
| Limited | |
| High |
Analysts expect SPRO's losses to shrink, with revenue holding steady.
SPRO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.49 | +$0.30 |
| Q2 2026 | $0.14 | +$1.12 |
| Q1 2026 | $0.27 | +$1.55 |
| Q4 2025 | $0.15 | +$1.42 |
| Q3 2025 | -$0.79 | -1088% |
| Q2 2025 | -$0.98 | -388% |
| Q1 2025 | -$1.28 | -391% |
| Q4 2024 | -$1.27 | -395% |
SPRO is still losing money, but far less than before: $0.49 per share over the past year, against $4.33 at its worst in mid-2020.
SPRO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q1 2026 | $258K | -96% |
| Q4 2025 | $41.3M | +175% |
| Q3 2025 | $5.4M | -60% |
| Q2 2025 | $14.2M | +39% |
| Q1 2025 | $5.9M | -37% |
| Q4 2024 | $15M | -80% |
| Q3 2024 | $13.5M | -47% |
| Q2 2024 | $10.2M | +275% |
SPRO's revenue fell from its 2023 peak and has held roughly level since: $0 last quarter, down 100% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q1 2026 | -2922% | -2671 points |
| Q4 2025 | 76% | +221 points |
| Q3 2025 | -145% | -7.4 points |
| Q2 2025 | -17% | +170 points |
| Q1 2025 | -251% | -100 points |
| Q4 2024 | -144% | -213 points |
| Q3 2024 | -138% | -130 points |
| Q2 2024 | -187% | +288 points |
SPRO's operating margin was −2922% last quarter, down 2671 points from the same quarter a year ago, near the bottom of its range since 2019.
SPRO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$42.6M | -345% |
| Q2 2026 | -$5.4M | +$12.3M |
| Q1 2026 | $15.9M | +$19.9M |
| Q4 2025 | -$8.4M | +$15.1M |
| Q3 2025 | $17.4M | +37% |
| Q2 2025 | -$17.7M | +$1.1M |
| Q1 2025 | -$4M | -167% |
| Q4 2024 | -$23.4M | -$5.9M |
SPRO has burned cash in most quarters: −$40M over the past year, against −$28M the year before.
SPRO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.4% | +261K shares |
| 1 year | +3.5% | +1.9M shares |
| 3 years | +10% | +5.5M shares |
| 5 years | +96% | +28.6M shares |
| Available history | +206% | +39.2M shares |
SPRO has 58M diluted shares, up 3.5% from a year ago.
SPRO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2024 | -4.1x | Net Cash |
| Q1 2024 | -3.7x | Net Cash |
| Q4 2023 | -3.5x | Net Cash |
SPRO has more cash than debt.
SPRO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 26.4 | Oversold |
| Stochastic | 9.2 | Oversold |
SPRO's weekly RSI is 26 (oversold) and its Stochastic is 9 (oversold).
SPRO PE vs Healthcare Sector
| Metric | SPRO | Sector median | Relative |
|---|---|---|---|
| PE | 7.4x | 26x | 72% below |
| PE % | 55 | 29 | 26 pts above |
SPRO has no meaningful PE right now: it lost money over the past year.
SPRO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.11 | 9.9% below |
| 20 week MA | $1.28 | 22% below |
| 50 week MA | $2.00 | 50% below |
| 100 week MA | $1.81 | 45% below |
| 200 week MA | $1.63 | 39% below |
SPRO is in a downtrend: it's below all five of its weekly moving averages, and 39% below its 200-week average.
SPRO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $10.4 | $22.0 | +111% |
| 2021 | $22.0 | $14.0 | -36% |
| 2022 | $14.0 | $1.59 | -89% |
| 2023 | $1.59 | $1.47 | -7.5% |
| 2024 | $1.47 | $1.03 | -30% |
| 2025 | $1.03 | $2.32 | +125% |
| 2026 YTD | $2.32 | $1.00 | -57% |
SPRO's yearly returns have swung widely, from +125% in 2025 to −89% in 2022. It's down 57% so far in 2026.